Machine learning models classify the likelihood of developing Alzheimer's.

Published Date: 05 Apr 2023

A new study suggests that once adults reach age 65, the cutoff age for Alzheimer's disease onset, the extent of their genetic risk may outweigh age as a predictor of whether they will experience the fatal brain disorder.

Read Full News

Latest News

Newborn Screening for Duchenne: Clinical and Policy Implications Marco Meglio

Paul Melmeyer, MPP, executive vice president, public policy and advocacy, Muscular Dystrophy Association, explains how adding Duchenne muscular dystrophy to the Recommended Unified Screening Panel reshapes early diagnosis, treatment timing, and family counseling.

Phase 3 VALOR Data Further Support Tofersen’s Impact on ALS Disease Progression, Survival Marco Meglio

Published phase 3 data in JAMA Neurology highlighted tofersen's potential to slow ALS progression and improve survival, marking a breakthrough in SOD1-ALS treatment.

FDA Approves Subcutaneous Copper Histidinate as First Treatment for Pediatric Menkes Disease Isabella Ciccone, MPH

The FDA approved Sentynl Therapeutics’ copper histidinate for the treatment of pediatric Menkes disease, a rare genetic neurodegenerative disorder, following an earlier complete response letter.

Rituximab Displays Long-Term Effectiveness for Relapsing MS Louie Pasculli

Annette Lenger-Gould, MD, PhD, lead for clinical and translational neuroscience at Kaiser Permanente, discusses findings and significance from a recently published trial assessing rituximab in patients with relapsing multiple sclerosis.

NeuroVoices: Nicholas Ashton, PhD, on Advances and Challenges in Alzheimer Disease Biomarkers Nicholas Ashton, PhD, Isabella Ciccone, MPH

The senior director of the Fluid Biomarker Program at Banner Health highlighted the evolving role of blood and fluid biomarkers in Alzheimer disease research and clinical practice.

High-Dose Nusinersen Gains European Commission Approval for Spinal Muscular Atrophy Louie Pasculli

The European Commission approved Biogen’s high-dose nusinersen regimen for 5q SMA, supported by DEVOTE trial data showing significantly improved motor function with a safety profile consistent with the standard-dose regimen.

Todays Updates

Amantadine Immediate Release Lowers Dyskinesia Risk in Early Parkinson Disease, Study Shows Louie Pasculli

Use of immediate-release amantadine as an add-on to levodopa reduced peak-dose dyskinesia incidence in patients with early Parkinson disease, according to results from the phase 2 PREMANDYSK trial.

NeurologyLive® Friday 5 — January 16, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 16, 2026.

Phase 1b Trial for Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Doses First Patient Noah Stansfield

The therapy also received orphan drug designation from the FDA.

Phase 3 MODIFY Shows No Significant Renal Benefit With Lucerastat in Fabry Disease

Phase 3 MODIFY Shows No Significant Renal Benefit With Lucerastat in Fabry Disease

HCPLive 5 Stories in Under 5: Week of 01/11

HCPLive 5 Stories in Under 5: Week of 01/11

Topical Antioxidant Serum May Be Effective in Treating Atrophic Acne Scars

Topical Antioxidant Serum May Be Effective in Treating Atrophic Acne Scars

Todays Updates

Amantadine Immediate Release Lowers Dyskinesia Risk in Early Parkinson Disease, Study Shows Louie Pasculli

Use of immediate-release amantadine as an add-on to levodopa reduced peak-dose dyskinesia incidence in patients with early Parkinson disease, according to results from the phase 2 PREMANDYSK trial.

NeurologyLive® Friday 5 — January 16, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 16, 2026.

Phase 1b Trial for Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Doses First Patient Noah Stansfield

The therapy also received orphan drug designation from the FDA.

Phase 3 MODIFY Shows No Significant Renal Benefit With Lucerastat in Fabry Disease

Phase 3 MODIFY Shows No Significant Renal Benefit With Lucerastat in Fabry Disease

HCPLive 5 Stories in Under 5: Week of 01/11

HCPLive 5 Stories in Under 5: Week of 01/11

Topical Antioxidant Serum May Be Effective in Treating Atrophic Acne Scars

Topical Antioxidant Serum May Be Effective in Treating Atrophic Acne Scars

Latest News

Paul Melmeyer, MPP, executive vice president, public policy and advocacy, Muscular Dystrophy Association, explains how adding Duchenne muscular dystrophy to the Recommended Unified Screening Panel reshapes early diagnosis, treatment timing, and family counseling.

Published phase 3 data in JAMA Neurology highlighted tofersen's potential to slow ALS progression and improve survival, marking a breakthrough in SOD1-ALS treatment.

The FDA approved Sentynl Therapeutics’ copper histidinate for the treatment of pediatric Menkes disease, a rare genetic neurodegenerative disorder, following an earlier complete response letter.

Annette Lenger-Gould, MD, PhD, lead for clinical and translational neuroscience at Kaiser Permanente, discusses findings and significance from a recently published trial assessing rituximab in patients with relapsing multiple sclerosis.

The senior director of the Fluid Biomarker Program at Banner Health highlighted the evolving role of blood and fluid biomarkers in Alzheimer disease research and clinical practice.

The European Commission approved Biogen’s high-dose nusinersen regimen for 5q SMA, supported by DEVOTE trial data showing significantly improved motor function with a safety profile consistent with the standard-dose regimen.

News All Time

Oral Anticoagulants Do Not Raise ARIA Risk of Anti-Amyloid Alzheimer Therapies, Study Shows Louie Pasculli

A review of clinical trial and real-world data found no evidence that oral anticoagulants increase brain imaging abnormalities in patients treated with lecanemab or donanemab for early Alzheimer disease.

NeurologyLive® Friday 5 — January 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 9, 2026.

Inside the 2026 MDA Conference: Emerging Research Themes in Neuromuscular Medicine Marco Meglio, Angela Lek, PhD

Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, provided an outlook on the 2026 MDA meeting and what clinicians should look forward to in preparation.

NeurologyLive® Brain Games: January 11, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on epilepsy comorbidities!

Key Neurology Trial Readouts to Watch in Early 2026 Isabella Ciccone, MPH

Review upcoming clinical trials with data readouts expected in the first half of 2026, providing updates relevant to ongoing research and clinical practice in neurology.

BMB-101 Heads for Registrational Trials Following Positive Phase 2 Data in Absence Seizures, Developmental Encephalopathies Marco Meglio

Bright Mind Biosciences reveals promising results for BMB-101 in treating drug-resistant seizures, paving the way for future clinical trials.

Episode 158: Bexicaserin, the PACIFIC Trial, and Treating Developmental Epileptic Encephalopathies Marco Meglio, Johannes Streffer, MD

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Johannes Streffer, MD. [LISTEN TIME: 14 minutes]

NeuroVoices: Christina Briscoe, MD; Emily Spelbrink, MD, PhD, on Addressing Equity Gaps in Infantile Epileptic Spasms Syndrome Marco Meglio, Christina Briscoe, MD, Emily Spelbrink, MD, PhD

A pair of pediatric epileptologists highlight the systemic and patient level factors driving inequities in infantile epileptic spasms syndrome care and outline paths toward more equitable diagnosis and treatment.

AES Poster Shines Light on Positive Phase 3 GEMZ Study of Fenfluramine in CDKL5 Deficiency Disorder Marco Meglio

Fenfluramine shows significant seizure reduction in CDKL5 deficiency disorder, offering hope for families facing treatment-resistant epilepsy challenges.

NeurologyLive®: Charting our 2026 Conference Coverage Louie Pasculli

Follow NeurologyLive's conference journey in 2026, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

Fenfluramine Treatment Leads to Long-Term Improved Everyday Executive Functioning in Lennox-Gastaut Syndrome Marco Meglio

A recent analysis reveals fenfluramine's positive effects on executive functioning in adults with Lennox-Gastaut syndrome, independent of seizure reduction.

GLP-1 Liraglutide Displays Effectiveness as Migraine Treatment in Early-Stage Study Louie Pasculli

In a pilot study, liraglutide, a drug used for diabetes and weight-loss, significantly reduced headache days in patients with obesity and chronic or high-frequency migraine, suggesting a potential new preventive therapy.

Claims Study Highlights Persistence and Reasons for Fenfluramine Use in Lennox-Gastaut Syndrome Marco Meglio

An AES study revealed the real-world persistence of fenfluramine in treating Lennox-Gastaut syndrome, highlighting patient demographics and treatment trends.

Fenfluramine’s Safety Profile Consistent in Long-Term Extension Dravet and Lennox-Gastaut Syndrome Studies Isabella Ciccone, MPH

Final safety data from an open-label study presented at AES 2025 supported long-term fenfluramine use in pediatric and adult patients with Dravet syndrome or Lennox-Gastaut syndrome.

FDA Approves Generic Glatiramer Acetate Injection for Multiple Sclerosis Treatment Marco Meglio

The newly approved generic product is expected to perform like other high-quality glatiramer acetate generics, with differences confined mainly to the manufacturer and device, not mechanism or dosing.

FDA Action Update, December 2025: Acceptance, Approval, and Clearance Isabella Ciccone, MPH

Catch up on any of the neurology news headlines you may have missed in December 2025, compiled into 1 place by the NeurologyLive® team.

Recommended News For You

High resolution ultrasound could enable faster prostate cancer diagnosis

combating racial discrimination in next-generation breast cancer screening.

Emicizumab in Infants With Hemophilia A: Safe and Effective Use.

Prior authorizations draining time, energy from many cancer patients

The risk of lung cancer recurrence is linked to hypoxemia brought on by sleep apnea.

Recent research suggests that vitamin supplements may increase the risk of developing cancer.

Since 2000, the outlook for multiple myeloma has improved.

Recommended Articles For You

Gut microbiota in curing cancer 

The Power of White Blood Cells: How They Help Keep Us Healthy 

Chemotherapy Advances: Albumin I.V., Trastuzumab, Liposomal Doxorubicin & More 

Exploring the Latest Treatments for Desmoid Tumors 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Making informed decisions and managing regret after prostate cancer treatment

2.

CAR-T cell therapy for cancer causes 'brain fog,' study shows

3.

FDA Approves CAR-T Product Use for Myeloma Early.

4.

Rural-urban disparities seen in cervical cancer

5.

Chemicals in Sewage Sludge Fertilizer Pose Cancer Risk, EPA Says

1.

Navigating the Unknown: A Guide to Living With Hurthle Cell Thyroid Cancer

2.

AI-Powered Rehabilitation: A Game Changer for Hemophilia Management

3.

Anesthetic Techniques and Strategies in Cancer Surgery: Unveiling the Impact on Oncological Outcomes

4.

The Importance of Maintaining Normal Calcium Levels in Your Body 

5.

The Bloodstream Compass: A Comparative Clinical Review of Liquid Biopsy and AI in Predictive Oncology

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Navigating the Complexities of Ph Negative ALL - Part II

2.

A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

3.

Updates on Standard V/S High Risk Myeloma Treatment- The Next Part

4.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective

5.

Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot